File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Der(8)t(1;8) in myeloblastic transformation of ET with hydroxyurea as the sole prior treatment

TitleDer(8)t(1;8) in myeloblastic transformation of ET with hydroxyurea as the sole prior treatment
Authors
Issue Date2005
PublisherJohn Wiley & Sons Ltd. The Journal's web site is located at http://www3.interscience.wiley.com/cgi-bin/jhome/3182
Citation
Hematological Oncology, 2005, v. 23 n. 2, p. 57-60 How to Cite?
AbstractWe described a patient with ET that evolved into MF and then subsequently developed myeloblastic transformation. A novel derivative chromosome der(8)t(1;8) was identified in the AML phase. The only prior treatment had been hydroxyurea. We hypothesized that AML in this case resulted from a complex pre-disposition by the natural progression of ET, prolonged use of HU, and the prior evolution into MF. The leukemogenic risk of HU is critically appraised. Copyright © 2005 John Wiley & Sons, Ltd.
Persistent Identifierhttp://hdl.handle.net/10722/76990
ISSN
2015 Impact Factor: 3.494
2015 SCImago Journal Rankings: 0.767
ISI Accession Number ID
References

 

DC FieldValueLanguage
dc.contributor.authorChim, CSen_HK
dc.contributor.authorMa, SKen_HK
dc.date.accessioned2010-09-06T07:27:05Z-
dc.date.available2010-09-06T07:27:05Z-
dc.date.issued2005en_HK
dc.identifier.citationHematological Oncology, 2005, v. 23 n. 2, p. 57-60en_HK
dc.identifier.issn0278-0232en_HK
dc.identifier.urihttp://hdl.handle.net/10722/76990-
dc.description.abstractWe described a patient with ET that evolved into MF and then subsequently developed myeloblastic transformation. A novel derivative chromosome der(8)t(1;8) was identified in the AML phase. The only prior treatment had been hydroxyurea. We hypothesized that AML in this case resulted from a complex pre-disposition by the natural progression of ET, prolonged use of HU, and the prior evolution into MF. The leukemogenic risk of HU is critically appraised. Copyright © 2005 John Wiley & Sons, Ltd.en_HK
dc.languageengen_HK
dc.publisherJohn Wiley & Sons Ltd. The Journal's web site is located at http://www3.interscience.wiley.com/cgi-bin/jhome/3182en_HK
dc.relation.ispartofHematological Oncologyen_HK
dc.rightsHematological Oncology. Copyright © John Wiley & Sons Ltd.en_HK
dc.subject.meshCell Transformation, Neoplasticen_HK
dc.subject.meshChromosome Aberrationsen_HK
dc.subject.meshChromosomes, Human, Pair 1en_HK
dc.subject.meshChromosomes, Human, Pair 8en_HK
dc.subject.meshHumansen_HK
dc.subject.meshHydroxyurea - therapeutic useen_HK
dc.subject.meshKaryotypingen_HK
dc.subject.meshLeukemia, Myeloid - etiology - geneticsen_HK
dc.subject.meshMaleen_HK
dc.subject.meshMiddle Ageden_HK
dc.subject.meshThrombocytosis - drug therapy - pathologyen_HK
dc.subject.meshTranslocation, Geneticen_HK
dc.titleDer(8)t(1;8) in myeloblastic transformation of ET with hydroxyurea as the sole prior treatmenten_HK
dc.typeArticleen_HK
dc.identifier.openurlhttp://library.hku.hk:4550/resserv?sid=HKU:IR&issn=0278-0232&volume=23&issue=2&spage=57&epage=60&date=2005&atitle=Der(8)t(1;8)+in+myeloblastic+transformation+of+ET+with+hydroxyurea+as+the+sole+prior+treatmenten_HK
dc.identifier.emailChim, CS:jcschim@hku.hken_HK
dc.identifier.authorityChim, CS=rp00408en_HK
dc.description.naturelink_to_subscribed_fulltext-
dc.identifier.doi10.1002/hon.750en_HK
dc.identifier.pmid16216034-
dc.identifier.scopuseid_2-s2.0-28844459313en_HK
dc.identifier.hkuros122125en_HK
dc.relation.referenceshttp://www.scopus.com/mlt/select.url?eid=2-s2.0-28844459313&selection=ref&src=s&origin=recordpageen_HK
dc.identifier.volume23en_HK
dc.identifier.issue2en_HK
dc.identifier.spage57en_HK
dc.identifier.epage60en_HK
dc.identifier.isiWOS:000234044600003-
dc.publisher.placeUnited Kingdomen_HK
dc.identifier.scopusauthoridChim, CS=7004597253en_HK
dc.identifier.scopusauthoridMa, SK=37020910400en_HK

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats